Baxter International Inc.

The Beth Israel Hospital Association

Other

Ty R Shockley

Leo Martis

Lee W Henderson

Masaaki Nakayama

John Moran

Janice Ann Nagy

Robert William Jackman

Chi J Chen

Ron Burke

Bernadette Faller

Miles G Johnston

A peritoneal dialysis solution comprising as osmotic agents approximately 2.0 to about 6.0% (w/v) maltodextrins and approximately 0.25 to about 2.0% (w/v) amino acids. The peritoneal dialysis solution will also include other components such as sodium, chloride, lactate, bicarbonate, calcium, and magnesium.

Peritoneal dialysis solutions containing maltodextrins and amino acids

Methods and pharmaceutical compositions for modifying the mesothelial cells of a mammalian recipient in situ are provided. The methods include forming a mesothelial cell expression system in vivo or ex vivo and administering the expression system to the mammalian recipient (by way of the body cavities normally lined by mesothelial cells). The mesothelial cell expression system is useful for the localized and systemic delivery of therapeutic agents in situ.

Mesothelial cell gene therapy

The present invention provides a peritoneal dialysis solution that contains atrial natriuretic peptide (ANP), a derivative of ANP, an analogue of ANP, a substance that binds ANP to clearance receptors or a substance that promotes ANP synthesis, which results in an increased net ultrafiltration and increased sodium clearance experienced in peritoneal dialysis patients.

Atrial natriuretic peptide (ANP) as an additive to peritoneal dialysis

An improved peritoneal dialysis solution and methods of administering same to a patient are provided. Pursuant to the present invention, the sodium concentration in the solution is decreased thus causing sodium to be transported from the circulation to the peritoneal cavity. This provides for an improved ultrafiltration profile for the same initial osmolality when compared to standard solutions. Also, the same ultrafiltration profile as standard solutions can be achieved with lower initial osmolalities.

Low sodium peritoneal dialysis solution

An improved peritoneal dialysis solution comprising an osmotic agent having at least one amino acid, and a method of administering same to a patient are provided. Pursuant to the present invention, the sodium concentration in the solution is decreased thus causing sodium to be transported from the circulation to the peritoneal cavity. This provides for an improved ultrafiltration profile that is, more volume over a longer period of time, for the same initial osmolality when compared to standard solutions. Also, the same ultrafiltration profile as standard solutions can be achieved with lower initial osmolalities.

A peritoneal dialysis solution and method of administering same to a patient are provided wherein the sodium concentration in the solution is decreased thus causing sodium to be transported from the circulation to the peritoneal cavity. This provides for an improved ultrafiltration profile (more volume over a longer period of time) for the same initial osmolality when compared to standard solutions. Also, the same ultrafiltration profile as standard solutions can be achieved with lower initial osmolalities. A reduced amount of osmotic agent can be used to achieve equivalent ultrafiltration.

Growing community of inventors

Highland Park, IL, United States of America

Ty R Shockley